Press Releases for ACOR

Press Releases
Acorda Therapeutics Reports Third Quarter 2009 Financial Results
PicksThatMove.Com Announces Investment Opinion Hot Stocks on NVNC, MPG, ACOR, KNA and ROYL
Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development
Acorda Therapeutics Reports Second Quarter 2009 Financial Results
Acorda Therapeutics to Host Conference Call to Report Second Quarter 2009 Financial Results on August 4, 2009
Biogen Idec Reports Second Quarter 2009 Results
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Acorda Therapeutics Announces Eligibility of Fampridine-SR for Centralized Review in Europe
Acorda Therapeutics Reports First Quarter 2009 Financial Results
Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing
Study Highlights Economic Impact of Early Mobility Impairment in People with Multiple Sclerosis
Acorda Therapeutics to Host Conference Call to Report First Quarter 2009 Financial Results on May 6, 2009
Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
Acorda Therapeutics to Present at the New York Biotechnology Association 18th Annual Meeting
Acorda Therapeutics Names Anthony Caggiano Vice President, Preclinical Development
Zacks Bull &Amp; Bear of the Day Highlights: Acorda Therapeutics, The St. Joe Company, Citigroup, Bank of America and Wells Fargo
Zacks Analyst Blog Highlights: The Governor and Company of the Bank of Ireland, Eli Lilly &Amp; Co., Acorda Therapeutics, Linktone and Chesapeake Energy Corp.
Zacks Analyst Blog Highlights: The Governor and Company of the Bank of Ireland, Eli Lilly &Amp; Co., Red Robin Gourmet Burgers, China Life Insurance Company Ltd., And Acorda Therapeutics.
Acorda Therapeutics Receives Refuse to File Letter from FDA on Fampridine-SR NDA
Over 80 Life Science Industry Exhibitors at the NYBA Annual Meeting
Acorda Therapeutics to Present at the Cowen and Company 29th Annual Health Care Conference
Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis
Zacks Analyst Blog Highlights: Acorda Therapeutics, Trimble Navigation Ltd., Petrobras, China Petrochemical Corporation and Foster Wheeler AG.
Acorda Therapeutics Reports Fourth Quarter and Full Year 2008 Financial Results
Acorda Therapeutics to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009
Acorda Therapeutics to Present at the 11th Annual BIO CEO & Investor Conference
Acorda Therapeutics Submits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
Acorda Therapeutics Provides 2009 Business and Pipeline Update at 27th Annual JPMorgan Healthcare Conference
Acorda Therapeutics to Present at the 27th Annual JPMorgan Healthcare Conference
Acorda Therapeutics to Present at RBC Capital Markets Healthcare Conference
Acorda Therapeutics Elects John P. Kelley to Board of Directors
Acorda Therapeutics to Present at the Piper Jaffray 20th Annual Healthcare Conference
Acorda Therapeutics to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer
Acorda Therapeutics to Present at the 2008 Deutsche Bank Biotech Boston Confab
Acorda Therapeutics Reports Third Quarter 2008 Financial Results
Acorda Therapeutics to Present an Overview of its Preclinical Pipeline at Windhover Therapeutic Area Partnerships Conference
Acorda Therapeutics to Host Conference Call to Report Third Quarter 2008 Financial Results on November 4, 2008
Zacks Analyst Blog Highlights: AstraZeneca PLC, Phase Forward, Omnicom Group, Acorda Therapeutics and Digital River, Inc.
Zacks Analyst Blog Highlights: Jones Soda Co., Raytheon Co., Georgia Gulf Corp., Avis Budget Group Inc. And Acorda Therapeutics Inc. - Sep 25 2008 2:19PM
Zacks Bull and Bear of the Day Highlights: ReneSola, Ltd. - ADS, Acorda Therapeutics, Avis Budget Group, Raytheon and Sara Lee Corp.
Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis
Acorda Therapeutics to Present at the UBS Global Life Sciences Conference
Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting
Acorda Therapeutics to Present at the Baird's 2008 Small Cap Health Care Conference
Acorda Therapeutics to Present at the 3rd Annual Citi Biotech Day Conference
Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most Promising Neuroscience Projects Available for Partnering by Windhover
Acorda Therapeutics, Inc. Announces Exercise of Option by Underwriter
Acorda Therapeutics, Inc. Announces Pricing of Common Stock Offering
Acorda Therapeutics Reports Second Quarter 2008 Financial Results
Acorda Therapeutics to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Acorda Therapeutics Presents Positive Data from Preclinical Studies of Neuregulins in Cardiac Function
Acorda Therapeutics to Host Conference Call to Report Second Quarter 2008 Financial Results on August 5, 2008
Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive Committee of Biotechnology Industry Organization (BIO)
Equity Spotlight for Tuesday, June 03, 2008: NPHS Best Performance!
Market Pulse Breaking News Alert for Tuesday, June 3, 2008: NCEN – NACEL Energy Achieves Objectives With 640 MW Wind Power in Development, Sets New 1000 MW Target and Prepares for Rapid Expansion!
BellwetherReport.com Analyst Report on ACOR, CNXT, PPHM and ABMD
Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
New York Biotechnology Association Executive Director and Biotechnology Industry Leaders to Ring The NASDAQ Stock Market Opening Bell
Acorda Therapeutics Reports First Quarter 2008 Financial Results - Jun 1 2008 6:30AM
Acorda Therapeutics to Present at Two Upcoming Conferences - Jun 1 2008 6:30AM
Acorda Therapeutics to Present at the Deutsche Bank 33rd Annual Health Care Conference
Acorda Therapeutics to Host Conference Call to Report First Quarter 2008 Financial Results on May 5, 2008
Acorda Therapeutics to Host Analyst and Investor Breakfast
Acorda Therapeutics Signs GGF2 Manufacturing Agreement with CMC ICOS
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing